Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DYADIC INTERNATIONAL, INC.

(DYAI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Dyadic International, Inc.’s C1 Production Platform Utilized in ZAPI Study Published in VACCINES

06/28/2021 | 08:30am EDT

Dyadic International, Inc. announced findings from the Zoonotic Anticipation and Preparedness Initiative (ZAPI) project which has been published in VACCINES, a leading peer-reviewed scientific journal. The successful ZAPI program focused on the following goals to enable the delivery of targeted vaccines for humans and animals, as well as therapeutic antibodies for hospital use, rapidly following a future disease outbreak by: Identifying the best protective subunit vaccines and neutralizing antibodies against potential new zoonotic diseases or strains, such as bunyaviruses (i.e., Rift Valley fever virus and Schmallenberg virus) or coronaviruses (i.e., Middle East respiratory syndrome coronavirus or MERS Co-V). Defining optimal manufacturing technologies and processes for these vaccines and antibodies to enable high-volume production capacity. Obtaining alignment with regulatory authorities and policy makers; and Securing pre-approval of new vaccine and antibody manufacturing methodologies for future emerging zoonotic viral diseases. The peer-reviewed study demonstrates the successful use of company’s patented and proprietary C1-cell protein production platform to facilitate a fast, coordinated, and practical response to new infectious diseases as soon as they emerge.


© S&P Capital IQ 2021
All news about DYADIC INTERNATIONAL, INC.
09/16DYADIC INTERNATIONAL : BPI East September 2021
PU
09/11DYADIC INTERNATIONAL : H.C. Wainwright 23rd Annual Global Investment Conference
PU
09/10DYADIC INTERNATIONAL : to Present at H.C. Wainwright 23rd Annual Global Investme..
AQ
08/19SORRENTO THERAPEUTICS : vaccine shows promise against coronavirus, variants in a..
RE
08/19SORRENTO THERAPEUTICS : Dyadic COVID-19 Vaccine Candidate Elicits "Strong" Immun..
MT
08/17DYADIC INTERNATIONAL : Insider Sale Slows Buying Trend of Last Quarter at Dyadic..
MT
08/16INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Dyadic Inter..
MT
08/12DYADIC INTERNATIONAL : Reports Second Quarter 2021 Financial Results and Highlig..
PU
08/12DYADIC INTERNATIONAL : Reports Second Quarter 2021 Financial Results and Highlig..
PU
08/12DYADIC INTERNATIONAL : Management's Discussion and Analysis of Financial Conditi..
AQ
More news
Financials (USD)
Sales 2021 3,00 M - -
Net income 2021 -11,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -12,5x
Yield 2021 -
Capitalization 151 M 151 M -
Capi. / Sales 2021 50,3x
Capi. / Sales 2022 45,7x
Nbr of Employees 6
Free-Float 49,2%
Chart DYADIC INTERNATIONAL, INC.
Duration : Period :
Dyadic International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DYADIC INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 5,37 $
Average target price 10,00 $
Spread / Average Target 86,2%
EPS Revisions
Managers and Directors
Mark A. Emalfarb President, Chief Executive Officer & Director
Ping W. Rawson Chief Financial Officer
Michael P. Tarnok Chairman
Ronen Tchelet Vice President-Research & Business Development
Seth J. Herbst Independent Director
Sector and Competitors
1st jan.Capi. (M$)
DYADIC INTERNATIONAL, INC.-0.19%151
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420